FDA approved osimertinib for the 1st-line treatment of patients with EGFR exon 19 deletions or exon 21 L858R mutations positive metastatic non-small cell lung cancer (NSCLC)

 

1 reply

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply